
Andrew Garbarino
U.S. Representative for New York's 2nd District
Republican · Since 2021 · Next election: 2026 · Age 42
Official name: Andrew R. Garbarino
Last updated · 7 sources
Andrew Garbarino is the U.S. Representative for New York's 2nd District, a Republican serving since 2021.
Garbarino has served in the House longer than 161 of its 438 other members and longer than 12 of New York's 25 other House members.
Garbarino chairs the Homeland Security Committee and also sits on Ethics and Financial Services.
In the House's last 30 days in session (May 19 – Oct 2, 2026), Garbarino voted in 139 of 139 roll calls (100%). In that period, 48 bills Garbarino sponsored or cosponsored had new actions.
Garbarino has filed with the FEC to run for this seat in 2026. 5 candidates for the seat have reported receipts to the FEC.
This week (Sep 28 – Oct 4, 2026)
Full schedule →House: pro forma sessions Mon and Thu
Votes
All of them →Voted in 139 of 139 roll calls (100%), May 19 – Oct 2, 2026.
Garbarino voted with the majority of House Republicans on 132 roll calls and against it on 7.
Votes against the party majority (latest 5 of 7)
| Date | Vote | Question | Result | Andrew Garbarino | Note |
|---|---|---|---|---|---|
| Jul 22 | No. 276 | On Agreeing to the Amendment H.R. 8800 | Failed | Nay | Most House Republicans: Yea |
| Jul 22 | No. 274 | On Agreeing to the Amendment H.R. 8800 | Failed | Nay | Most House Republicans: Yea |
| Jul 21 | No. 269 | On Agreeing to the Amendment H.R. 8800 | Failed | Nay | Most House Republicans: Yea |
| Jul 15 | No. 245 | On Agreeing to the Amendment H.R. 8595 | Failed | Nay | Most House Republicans: Yea |
| Jul 15 | No. 242 | On Agreeing to the Amendment H.R. 8595 | Failed | Nay | Most House Republicans: Yea |
Legislation
40 bills sponsored and 269 cosponsored in the 119th Congress
H.R. 10678 To permit the Byrne JAG grant to be used for the purchase of fentanyl testing kits and opioid reversal agents.
Cosponsor · Latest action Oct 1, 2026: Referred to the House Committee on the Judiciary.
H.R. 8205 Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026
Cosponsor · Latest action Sep 28, 2026: Passed Senate without amendment by Voice Vote. (consideration: CR S5120)
This bill reauthorizes through FY2031 and revises programs that support research and development of drugs and other therapies to address amyotrophic lateral sclerosis (also known as ALS or Lou Gehrig's disease) and other neurodegenerative diseases.
H.R. 10553 Margin Eligibility Modernization Act
Sponsor · Latest action Sep 24, 2026: Referred to the House Committee on Financial Services.
Campaign finance
- Raised
- $3,513,016
- Spent
- $1,599,708
- Cash on hand
- $3,458,915
2026 election cycle, through Jun 30, 2026 · FEC H0NY02234
New York senators
Chuck SchumerU.S. Senator for New York · Democrat
Kirsten GillibrandU.S. Senator for New York · Democrat
Sources
- congress-legislators (member data, CC0) · retrieved Oct 2, 2026
- Portrait: Public domain (U.S. government work)
- House roll-call votes (Office of the Clerk)
- Bill status (Congress.gov / GovInfo BILLSTATUS) · retrieved Oct 2, 2026
- Campaign finance (Federal Election Commission) · retrieved Oct 2, 2026
- District profile (Census Bureau, 2020–2024 American Community Survey 5-year estimates)